Codexis Reports Robust Q4 2025 Financials, Outlines Ambitious RNA Medicine Strategy
San Francisco-based biotechnology company Codexis has reported strong fourth-quarter and fiscal year 2025 financial results, with the company's focus on RNA medicine gaining significant momentum.
In a conference call to discuss the Q4 2025 earnings, Dr. Alison Moore, President and CEO of Codexis, highlighted the company's mission to generate manufacturing solutions using biocatalytic enzymes, with a particular emphasis on RNA medicine.
Codexis has developed the ECO Synthesis manufacturing platform, designed to address the challenges experienced with current siRNA production technology. The number of siRNA medicines in development is growing at a rate of 5-10% per year, and Codexis aims to establish itself as a key technology provider in this market.
The total addressable annual market for production technologies in five years is estimated to be $2 billion, with the company's ECO Synthesis platform positioned to capture a significant share. Last year was pivotal in both the focus and momentum of the company, with Codexis achieving several important milestones in platform performance and industry engagement.
Codexis has demonstrated its leadership in biocatalytic enzyme innovation by developing technologies that can improve large-scale manufacturing of oligonucleotides and potentially deliver superior therapeutic asset activity. A significant technical milestone was reached when the company synthesized 10 grams of a commercially relevant siRNA using full sequential ECO Synthesis.
In addition, Codexis shared detailed product quality data from this synthesis, demonstrating no quality barriers related to its production technology. The company is continuing to scale up the production platform in 2026, currently operating at 100-gram scale in its Eco Innovation Lab and heading toward half a kilo scale by the end of the year.
Furthermore, a client utilized Codexis's ligase to manufacture a 3-kilogram batch of siRNA, a tremendous achievement in chemoenzymatic production. The company has also made significant progress in building a robust supply chain to support its ECO Synthesis platform, including modernizing its non-GMP production capability and achieving ISO 9001 certification.
This milestone provides confidence to customers that Codexis is operating under a particular quality standard. The company has passed a facility and quality management system inspection by a large pharmaceutical customer, readying Codexis for ECO enzyme supply.
